Oral 5-Aminosalicylates Will Continue to be Used in Early Lines of Therapy, According to a New Report from Decision Resources
WALTHAM, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade is currently the leading biologic for Crohn's disease, but Abbott/Eisai's Humira will soon become the first-choice among biologics.
Patient-level claims data indicate that Remicade currently captures a larger share of Crohn's disease patients on every line of therapy than Humira. However, 56 and 65 percent of surveyed gastroenterologists and primary care physicians say that, over the next two years, they will increase their use of Humira on the first and second lines of therapy, respectively. This shift will occur because Humira is easier to use--it can be self injected in the privacy of one's home versus having to go to the physician's office as is the case with Remicade which is administered intravenously. In addition, both gastroenterologists and primary care physicians say they will increase their use of Humira as a maintenance therapy.
According to interviewed experts, physicians are increasingly moving patients to biologics early in treatment.
"Moving up in lines of therapy means an expanded potential patient population for these agents," stated Michael Malecki, Ph.D., analyst at Decision Resources. "Because biologics are much more expensive than conventional agents, the trend of using them earlier in therapy will result in a net market expansion in terms of dollars."
The new report entitled Treatment Algorithms in Crohn's Disease also
finds that oral 5-aminosalicylates will continue to be used in early lines
of therapy for patients with mild disease. Among oral 5-aminosalicylates,
Shire's Lialda has more convenient dosing. Because of this clinical
advantage, surveyed p
|SOURCE Decision Resources|
Copyright©2008 PR Newswire.
All rights reserved